Results 21 to 30 of about 2,870,340 (221)

Phosphodiesterase inhibitors [PDF]

British Journal of Pharmacology, 2006
Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire   +4 more sources

The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors

Andrology, 2022
Erectile dysfunction is associated with diabetes mellitus with an estimated prevalence of 52.5% in the diabetic population. The first‐line therapy for erectile dysfunction is phosphodiesterase type 5 inhibitors, but data suggest that diabetic men may be ...
A. Cayetano-Alcaraz, T. Tharakan, Runzhi Chen, N. Sofikitis, S. Minhas   +4 more
semanticscholar   +1 more source

Multi-target Natural and Nature-Inspired Compounds against Neurodegeneration: A Focus on Dual Cholinesterase and Phosphodiesterase Inhibitors

Applied Sciences, 2021
Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo, Maurizio Memo, Alessandra Gianoncelli   +2 more
doaj   +1 more source

Theophylline and phosphodiesterase inhibitors [PDF]

European Respiratory Journal, 1995
Michel Aubier, Peter J. Barnes
openalex   +4 more sources

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors

Pulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake   +6 more
doaj   +1 more source

Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review

Dermatologic Therapy, 2020
Due to immune‐mediated nature, medicines with immunomodulatory and anti‐inflammatory effects can used to treat many dermatologic diseases. Phosphodiesterase and prostaglandins are involved in many inflammatory pathways that cause cutaneous disorders ...
Nafise Yazdanian, Samaneh Mozafarpoor, A. Goodarzi   +2 more
semanticscholar   +1 more source

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study

Pulmonary Circulation, 2020
Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson, Oisin Butler, Roger Hesselstrand, Katsiaryna Holl, Kjell Jansson, Rogier Klok, Göran Rådegran, Stefan Söderberg, Barbro Kjellström   +8 more
doaj   +1 more source

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

Frontiers in Pharmacology, 2020
Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova, Vladimir Calkovsky, Heiko Pedan, Estera Behanova, Andrej Hajtman, Andrea Calkovska   +5 more
doaj   +1 more source

PDE5 inhibitor drugs for use in dementia

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth, Ottavio Arancio, Fanny M. Elahi, Jeremy D. Isaacs, Feixiong Cheng   +4 more
doaj   +1 more source

Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors

Brazilian Journal of Pharmaceutical Sciences, 2020
Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem, Muhammad Saleem, Sheikh Arshad Saeed   +2 more
doaj   +1 more source